NICE Pans Roche’s Perjeta For Breast Cancer On Clinical, Cost Grounds
This article was originally published in The Pink Sheet Daily
Executive Summary
Roche’s Perjeta suffered a knock-back in Europe when NICE said the clinical trial population was not wholly relevant to the patient population in the UK.